Akeso, Inc. (HKG:9926)
70.95
+2.50 (3.65%)
Mar 27, 2025, 4:08 PM HKT
Akeso Revenue
Akeso had revenue of 1.02B CNY in the half year ending June 30, 2024, with 528.16% growth. This brings the company's revenue in the last twelve months to 1.87B, down -56.93% year-over-year. In the year 2023, Akeso had annual revenue of 4.53B with 440.35% growth.
Revenue (ttm)
1.87B CNY
Revenue Growth
-56.93%
P/S Ratio
29.64
Revenue / Employee
674.64K CNY
Employees
2,778
Market Cap
63.68B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 29.60B |
Hansoh Pharmaceutical Group Company | 13.05B |
WuXi Biologics | 18.39B |
JD Health International | 61.89B |
Alibaba Health Information Technology | 31.39B |
Innovent Biologics | 8.01B |
Sino Biopharmaceutical | 30.72B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
Akeso News
- 11 days ago - Chinese drug maker Akeso hailed as biotech's 'DeepSeek moment' amid US competition - Yahoo
- 12 days ago - Chinese drug maker Akeso hailed as biotech’s ‘DeepSeek moment’ amid US competition - South China Morning Post
- 4 months ago - BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential - Benzinga
- 5 months ago - Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo - Benzinga